Aclaris Therapeutics Inc
ACRS
Get informed when a big investor buys or sells
+ FollowMarket Cap$684.98M
Close$
$-0.95
117% downside
Current Fair Value
117% downsideOvervalued by 117% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $684.98 Million |
|---|---|
| Enterprise Value | $662.28 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.53 |
| Beta | 0.77 |
| Outstanding Shares | 128,810,050 |
Return
| Return on Equity | -48.49% |
|---|---|
| Return on Assets | -35.06% |
| Return on Invested Capital | -43.52% |
Valuation & Multiples
| P/E Ratio | -10.14 |
|---|---|
| PEG | -32.29 |
| Price to Sales | - |
| Price to Book Ratio | 5.62 |
| Enterprise Value to Revenue | 79.15 |
| Enterprise Value to EBIT | -8.88 |
| Enterprise Value to Net Income | -10 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.16
Average shareholder expectationRevenue Estimate
$1.24 M
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.16
Average shareholder expectationRevenue Estimate
$1.38 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 36.82% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.17%▼ 88.46% |
|---|---|
| Total Invested | $1.16M▼ 99.72% |
| Investors Holding | 8▼ 132.00% |
ESG Score
No data
About Aclaris Therapeutics Inc
CEO: Neal Walker